FDA Pearson Implementation Faces Further Congressional Criticism
This article was originally published in The Tan Sheet
Executive Summary
FDA's progress in implementing the Pearson v. Shalala court decision is sharply criticized by Republican Reps. Helen Chenoweth-Hage (Idaho), Ron Paul (Texas) and Bob Stump (Ariz.) in a March 17 letter to the agency.
You may also be interested in...
FDA 100-Day Health Claim Review Provided In House Bill
FDA would be required to authorize general health claims and "claims based on government statements" within 100 days of receipt under the "Consumer Freedom Protection Act." Currently, the agency has 540 days to review a proposed health claim.
FDA 100-Day Health Claim Review Provided In House Bill
FDA would be required to authorize general health claims and "claims based on government statements" within 100 days of receipt under the "Consumer Freedom Protection Act." Currently, the agency has 540 days to review a proposed health claim.
FDA 100-Day Health Claim Review Provided In House Bill
FDA would be required to authorize general health claims and "claims based on government statements" within 100 days of receipt under the "Consumer Freedom Protection Act." Currently, the agency has 540 days to review a proposed health claim.